Exelixis reported $215.68M in EBIT for its fiscal quarter ending in July of 2025.


Ebit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Amgen USD 2.26B 1.34B Jun/2025
AstraZeneca USD 3.51B 1.3B Jun/2025
Bayer EUR -36000000 2.95B Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Bristol-Myers Squibb USD 2.26B 1.92B Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
Eisai JPY 20.74B 1.77B Jun/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Exelixis USD 215.68M 28.82M Jul/2025
Genmab DKK 432M 900.27M Jun/2025
Glaxosmithkline GBP 2.07B 237.99M Jun/2025
Incyte USD 310.82M 27.18M Jun/2025
Ionis Pharmaceuticals USD 144.78M 290.78M Jun/2025
MacroGenics USD -35344000 17.49M Jun/2025
Merck USD 6.36B 149M Jun/2025
Moderna USD -817000000 146M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD -9190000000 13.87B Jun/2025
Pfizer USD 2.6B 3.33B Jun/2025
Sanofi EUR 1.51B 704.8M Jun/2025
Takeda JPY 257.79B 387.52B Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Xencor USD -22832000 16.77M Jun/2025